UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Apr. 30, 2022	May 01, 2021
Cash flows from operating activities:
Net loss	$ (165,700)	$ (88,200)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	75,700	51,800
Stock-based compensation	131,100	92,700
Amortization of acquired intangible assets	272,500	128,600
Amortization of inventory fair value adjustment associated with acquisitions	9,300	13,700
Other expense, net	6,700	31,400
Deferred income taxes	165,000	(22,600)
Changes in assets and liabilities, net of acquisitions:
Accounts receivable	(139,500)	(58,000)
Prepaid expenses and other assets	(142,900)	4,400
Inventories	(125,800)	(13,200)
Accounts payable	61,400	(51,600)
Accrued employee compensation	(50,000)	(55,700)
Accrued liabilities and other non-current liabilities	97,000	(47,000)
Net cash provided by (used in) operating activities	194,800	(13,700)
Cash flows from investing activities:
Purchases of technology licenses	(1,600)	(3,400)
Purchases of property and equipment	(36,900)	(21,400)
Acquisitions, net of cash acquired	(44,000)	(3,600,200)
Other, net	100	400
Net cash used in investing activities	(82,400)	(3,624,600)
Cash flows from financing activities:
Repurchases of common stock	(15,000)	0
Proceeds from employee stock plans	2,500	500
Tax withholding paid on behalf of employees for net share settlement	(137,600)	(73,200)
Dividend payments to stockholders	(50,900)	(40,600)
Payments on technology license obligations	(49,000)	(44,100)
Proceeds from issuance of debt	0	3,731,100
Principal payments of debt	(10,900)	(200,000)
Payment for repurchases and settlement of convertible notes	0	(71,100)
Proceeds from capped calls	0	111,200
Payment of equity and debt financing costs	0	(1,500)
Net cash provided by (used in) financing activities	(260,900)	3,412,300
Net decrease in cash and cash equivalents	(148,500)	(226,000)
Cash and cash equivalents at beginning of period	613,500	748,500
Cash and cash equivalents at end of period	$ 465,000	$ 522,500